Thursday, 30 April 2015
Time |
HALL A - Plenary Room “Terpsichore A&B” |
||
13.00 - 14.00 | Lunch Company Sponsored Symposium I: RANK Ligand inhibition in skeletal oncology
Chair: Thomas Brodowicz, Austria 13.00–13.05 Welcome and introduction | Thomas Brodowicz, Austria 13.05–13.20 Targeting cancer-related bone disease with RANK Ligand inhibition | Thomas Brodowicz, Austria 13.20–13.35 Pain, quality of life and the bone | Athina Vadalouka, Greece 13.35–13.50 Advancing treatment options in giant cell tumour of bone | Javier Martin-Broto, Spain 13.50–14.00 Q&A |
Time |
HALL A - Plenary Room “Terpsichore A&B” |
||
14.00 - 15.00 | Company Sponsored Symposium II:
Evidence Guided Treatment Decisions Welcome and introduction | Stefan Sleijfer Current treatment landscape in aSTS | Stefan Sleijfer The role of clinical trials in advancing treatment for aSTS | Patrick Schöffski Moving into everyday clinical practice: experience outside of the clinical trial setting | Hans Gelderblom Panel discussion and Q&A | ALL Summary & meeting close | Stefan Sleijfer Faculty: Professor Stefan Sleijfer, MD, PhD Professor of Medical Oncology, Erasmus MC-Cancer Institute, Rotterdam, The Netherlands Professor Patrick Schöffski, MPH Head, Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven Full professor, Faculty of Medicine, Department of Oncology, Head, Research Unit Laboratory of Experimental, Oncology, KU Leuven, Belgium Professor Hans Gelderblom Professor of Clinical Oncology Leiden University Medical Center, Leiden, The Netherlands |
Time |
HALL A - Plenary Room “Terpsichore A&B” |
||||||||||||||||||
15.00 - 16.00 | Company Sponsored Symposium III:
Chair: P.J.Papagelopoulos, Athens University Greece
|